Integrated global pharmaceutical company Dr. Reddy's Laboratories has introduced divalproex sodium extended - release tablets, USP, in 250mg and 500mg strengths in the US.
The new FDA approved product is the generic version of Depakote ER (divalproex sodium) tablet, extended release. Depakote ER tablet is a trademark of Sanofi.
Dr. Reddy's has made Divalproex Sodium Extended - Release Tablets, USP 250mg available in bottle count sizes of 100 and 500mg in bottle count sizes of 100 and 500.
The US sales for Depakote ER brand and generic for the most recent twelve months ending in June 2013, according to IMS Health was approximately $194m MAT.
Dr. Reddy's through its three businesses, Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products, offers a portfolio of products and services, including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.
Its major markets include India, US, Russia and CIS, Germany, UK, Venezuela, South Africa, Romania, and New Zealand.
